Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FENXN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $56,605
Award facts
- Contract value 100% obligated
- $56,604.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $56,604.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, issued on December 15, 2025, with an ultimate completion date of December 18, 2025, represents one of numerous pharmaceutical supply orders placed under DMS Pharmaceutical Group's larger prime vendor contract. The award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will supply pharmaceutical products and medical consumables to support Department of Defense healthcare operations, with performance to be conducted at the company's Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceuticals and medical consumables to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's product portfolio includes branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals such as oncology treatments, immunosuppressants, and emergency medications, positioning the company as a critical supplier within the federal military pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DU26FENXN?
SPE2DU26FENXN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DU26FENXN worth?
The government has obligated $56,605 on SPE2DU26FENXN.
Is contract SPE2DU26FENXN an order under another contract?
Yes. SPE2DU26FENXN is a delivery order under SPE2DU25D9418, an indefinite delivery contract.
Was contract SPE2DU26FENXN competed?
The extent of competition for SPE2DU26FENXN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award